Treatment of relapsed hyperthyroidism

Jae Hoon Chung

doi:10.5124/jkma.2018.61.4.248

J Korean Med Assoc > Volume 61(4); 2018 > Article

Chung: Treatment of relapsed hyperthyroidism

Original Article

J Korean Med Assoc 2018; 61(4): 248-252.

Published online: April 17, 2018

DOI: http://dx.doi.org/10.5124/jkma.2018.61.4.248

Treatment of relapsed hyperthyroidism

Jae Hoon Chung, MD^1,²

¹Division of Endocrinology & Metabolism, Department of Internal Medicine, Seoul, Korea

²Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Corresponding author: Jae Hoon Chung E-mail: thyroid@skku.edu

Received March 06, 2018 Accepted March 20, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Graves disease is the most common disease that causes hyperthyroidism. It is an autoimmune disease characterized by the overproduction of thyroid hormones due to continuous stimulation of the thyroid gland by thyroid-stimulating hormone receptor antibody. Therapeutic modalities for Graves disease include antithyroid drugs (ATDs), radioactive iodine, and thyroidectomy. ATDs are the most preferred therapeutic option by physicians in most countries except North America. However, current treatment strategies are unfortunately aimed at inhibiting thyroid hormone production or ablating the thyroid to induce permanent hypothyroidism, not at inhibiting thyroid-stimulating hormone receptor antibody. ATD therapy has a high relapse rate (more than 50%), and morbidity and mortality increase in cases of relapse. Therefore, the proper and prompt management of relapsed patients is very important.

Key words: Hyperthyroidism; Recurrence; Antithyroid agents; Iodine radioisotopes; Thyroidectomy

REFERENCES

1. Chung JH. Genetics of Gravesʼ disease. J Korean Soc Endocrinol 2003;18:5-11.

2. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS. Comparative effectiveness of therapies for Gravesʼ hyperthyroidism: a systematic review and network metaanalysis. J Clin Endocrinol Metab 2013;98:3671-3677.

3. Abraham-Nordling M, Torring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, Wallin G. Gravesʼ disease: a longterm quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 2005;15:1279-1286.

4. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-509.

5. Seo GH, Kim SW, Chung JH. Incidence & prevalence of hyperthyroidism and preference for therapeutic modalities in Korea. J Korean Thyroid Assoc 2013;6:56-63.

6. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M. Differences and similarities in the diagnosis and treatment of Gravesʼ disease in Europe, Japan, and the United States. Thyroid 1991;1:129-135.

7. Cho BY, Koh CS. Current trends in the diagnosis and treatment of Gravesʼ disease in Korea. J Korean Soc Endocrinol 1992;7:216-227.

8. Yi KH, Moon JH, Kim IJ, Bom HS, Lee J, Chung WY, Chung JH, Shong YK. The diagnosis and management of hyperthyroidism consensus: report of the Korean Thyroid Association. J Korean Thyroid Assoc 2013;6:1-11.

9. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med 1994;121:281-288.

10. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M. Longterm followup of patients with hyperthyroidism due to Gravesʼ disease treated with methimazole: comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 2008;31:866-872.

11. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Gravesʼ hyperthyroidism. Eur J Endocrinol 2005;153:489-498.

12. Japan Thyroid Association. Guideline for the treatment of Gravesʼ disease with antithyroid drug in Japan. Tokyo: Nanko-do; 2006.

13. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26:1343-1421.

14. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Gravesʼ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008;158:69-75.

15. Laurberg P, Krejbjerg A, Andersen SL. Relapse following antithyroid drug therapy for Gravesʼ hyperthyroidism. Curr Opin Endocrinol Diabetes Obes 2014;21:415-421.

16. Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR. Does smoking increase relapse rates in Gravesʼ disease? J Endocrinol Invest 2002;25:152-157.

17. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000;85:1038-1042.

18. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Gravesʼ disease. Eur J Endocrinol 2002;147:583-589.

19. Bolanos F, Gonzalez-Ortiz M, Duron H, Sanchez C. Remission of Graves' hyperthyroidism treated with methimazole. Rev Invest Clin 2002;54:307-310.

20. Orgiazzi J, Madec AM. Reduction of the risk of relapse after withdrawal of medical therapy for Gravesʼ disease. Thyroid 2002;12:849-853.

21. Glinoer D, de Nayer P, Bex M. Belgian Collaborative Study Group on Gravesʼ Disease. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001;144:475-483.

22. Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A. Remission of Gravesʼ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid 2000;10:891-896.

23. Cooper DS. Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance. Ann Intern Med 1985;102:328-331.

24. Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Gravesʼ disease. Am J Med 1995;99:173-179.

25. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Gravesʼ hyperthyroidism: standard vs. calculated 131iodine activity: results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995;25:186-193.

26. Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves' disease: A metaanalysis. J Surg Res 2000;90:161-165.

27. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228:320-330.

28. Sosa JA, Mehta PJ, Wang TS, Boudourakis L, Roman SA. A population-based study of outcomes from thyroidectomy in aging Americans: at what cost? J Am Coll Surg 2008;206:1097-1105.

29. Kim HI, Kim TH, Choe JH, Kim JH, Kim JS, Kim YN, Kim H, Kim SW, Chung JH. Surgeon volume and prognosis of patients with advanced papillary thyroid cancer and lateral nodal metastasis. Br J Surg 2018;105:270-278.